Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Plasma cell 2Breast 2Other hematologic neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 30Neoplasms, Plasma Cell 7Breast Neoplasms 5Prostatic Neoplasms 3Pain 3Spinal Cord Compression 2Hematologic Neoplasms 2Bone Neoplasms 2Bone Diseases 2Renal Insufficiency 1Paraproteinemias 1Osteonecrosis 1Osteolysis 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Hematologic Diseases 1Fractures, Bone 1Disease Progression 1Bone Marrow Diseases 1Blood Protein Disorders 1

Interventions

Zoledronic Acid 2Denosumab 2cabozantinib 1Exercise 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Diseases × Zoledronic Acid × Plasma cell × Clear all
NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Amgen

Phase 3 Completed
1,718 enrolled 22 charts
Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00741377 2013-02-18

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Novartis

Phase 1 Completed
28 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡